Sanofi.
SNY.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Sanofi is a global biopharmaceutical company focused on human health. The company researches, develops, manufactures, and markets a wide range of pharmaceutical products, including prescription drugs and vaccines. Sanofi's portfolio includes treatments for various therapeutic areas, such as diabetes...Show More
Better Health for All
20
Sanofi's core business as a biopharmaceutical company focused on human health, developing and marketing a wide range of prescription drugs and vaccines for various therapeutic areas and infectious diseases, indicates that the vast majority of its product portfolio delivers substantial health benefits. The company's operations do not generate revenue from products with significant negative health impacts. Sanofi demonstrates strong initiatives in healthcare workforce support, including training over 120 Community Outreach Agents in Zimbabwe
1
and supporting community health workers through a digital platform.
2
The company also shows comprehensive access frameworks through its Global Health Unit (GHU), a not-for-profit social business model launched in 2022,
3
which provides 30 essential medicines under the Impact® brand to 40 lower-income countries.
4
Additionally, its Insulin Valyou Savings Program offers uninsured individuals insulin at $35 for a 30-day supply in the US.
5
Furthermore, the company engages in excellent healthcare education initiatives, such as the "Kids and Diabetes in Schools (KiDS)" program, established in 2013 in partnership with the International Diabetes Federation,
6
and community outreach programs to empower communities with health knowledge.
7
Fair Money & Economic Opportunity
0
Sanofi is a biopharmaceutical company focused on human health, not a financial institution. The company does not offer lending, deposit services, consumer credit products, or other financial services to customers. Therefore, all Key Performance Indicators (KPIs) related to fair money and economic opportunity, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility, fair lending compliance, wealth building outcomes, profit reinvestment in community finance, financial literacy initiatives, debt burden ratio, geographic inclusion for banking, and product simplicity for financial products, are not applicable to its core business model.
Fair Pay & Worker Respect
30
As of 2024, Sanofi reports no employees are paid below the applicable adequate wage benchmark.
1
The CEO to median employee pay ratio was 166.3 in 2024.
2
In 2024, 48% of employees were covered by collective bargaining agreements.
3
The rate of recordable work-related accidents in its own workforce was 1.7 in 2024.
4
Sanofi had an average global pay gap of 5.5% in favor of women in 2024.
5
The employee engagement score was 7.6 out of 10 in 2024, with an 83% participation rate in the 'Your Voice' survey.
6
The resignation rate on permanent contracts was 4.0% in 2024.
7
In 2024, 30 substantiated cases of discrimination and harassment were reported, adding to 273 substantiated cases in 2023.
8
Fixed-term employees constituted 12.4% of the workforce in 2024.
9
The company states that all employees worldwide receive high-quality benefits covering health, and in general, their spouses and children receive medical expense reimbursement.
10
An Employee Assistance Program is available globally, offering confidential counseling.
11
Fair Trade & Ethical Sourcing
0
The provided articles outline Sanofi's commitment to ethical sourcing, human rights, and responsible business practices
1
, including risk mitigation strategies like due diligence, monitoring, and auditing for high-risk suppliers
2
. Sanofi utilizes Ecovadis for supplier sustainability assessments
3
and conducts ad-hoc due diligence for areas like conflict minerals
4
. However, no specific quantitative data is provided across the articles for any of the KPIs, such as the percentage of fair-trade certified spend, audit frequency, number of forced or child labor incidents, traceability coverage, remediation speed, ethical clause coverage in contracts, share of high-risk materials, or supplier diversity spend
5
.
Honest & Fair Business
20
Sanofi has a robust whistleblower protection policy, including a 24/7 helpline operated by a third-party vendor, available in multiple languages, which permits anonymous reporting and prohibits retaliation.
1
In 2024, 900 alerts were raised, leading to 396 substantiated cases and 141 dismissals or resignations.
2
The company maintains a zero-tolerance anti-corruption policy, requiring risk-based due diligence on business partners and providing compliance training to 81,058 employees in 2024.
3
Its sustainability report is certified by statutory auditors, and its energy and HSE management systems are ISO 50001:2018 and ISO 14001:2015 certified, respectively, indicating extensive third-party verification of ethical claims and management systems.
4
Approximately 82% of the board members are independent.
5
In 2024, a subsidiary incurred a late submission fee of approximately $125.
6
Additionally, a subsidiary had one financial restatement in 2023 due to a demerger.
7
Kind to Animals
0
Sanofi reported using 167,408 animals in 2024 (internal and external).
1
Despite this volume, the company has achieved a 48% reduction in animal use since 2020
2
and targets a 50% reduction by 2030,
3
with a global objective of zero animal testing in vaccine quality control by 2035.
4
Its animal testing policy restricts use to cases where non-animal methods are unsuitable or not accepted by authorities,
5
and it is committed to the 3Rs principles,
6
having banned the forced swim test.
7
The company actively employs and develops alternative testing methods, including in vitro methods for vaccine testing,
8
recombinant reagents,
9
Monocyte Activation Tests,
10
and virtual control groups in collaboration with Charles River.
11
Specific animal tests, such as the rabbit pyrogen test for Verorab vaccine, have been eliminated,
12
and one production site fully ended in vivo quality control, saving approximately 1,000 mice annually.
13
Regarding humane operations, 11 out of 12 Sanofi sites (91.67%) that house or use animals hold AAALAC International accreditation or comply with equivalent principles.
14
The company evaluated 100% of its 78 animal-related external partners, excluding one for non-compliance.
15
Sanofi participates as an active member in multi-stakeholder initiatives like the NHPig project to reduce non-human primate use
16
and is a signatory to the Marseille Declaration.
17
The company also advocates for the acceptance of new assays and alternative testing methods with regulators,
18
contributes to regulatory debates on animal protection rules,
19
and has signed Transparency Charters in several countries.
20
No War, No Weapons
-20
Sanofi has an R&D agreement with the Walter Reed Army Institute of Research, a U.S. Department of Defense biomedical research facility, to develop a Zika vaccine candidate.
1
Sanofi's centralized Procurement team follows a policy based on economic, ethical, environmental, and social principles and is an active member of the Pharmaceutical Supply Chain Initiative.
2
Suppliers are required not to use conflict minerals from the Democratic Republic of Congo or adjoining countries, or any other minerals identified as financing conflict under Section 13p of the U.S. Securities Exchange Act of 1934.
3
The company emphasizes risk-based due diligence, including audits and assessments for high-risk suppliers, and utilizes controls like monitoring, training, and auditing to prevent non-compliance.
4
Sanofi upholds international labor standards, ensuring compliance with ILO Core Labor Rights Conventions and UN Guiding Principles on Business and Human Rights, and upholds the Living Wage Ambition of the United Nations Global Compact.
5
Sanofi has Responsible AI Guiding Principles and requires AI systems to be designed for accuracy, robustness, and cybersecurity, with AI used across all Sanofi activities, particularly in medical and scientific research.
6
The Sanofi Bioethics Framework, established in 2012, sets high ethical standards for all scientific and medical activities.
7
Sanofi's lobbying expenditures are categorized under the Pharmaceuticals/Health Products industry.
8
Planet-Friendly Business
-20
Sanofi's total Scope 1, 2, and 3 greenhouse gas emissions were 4.389 M tCO₂e in 2024.
1
The company reported a 47% decrease in Scope 1 & 2 emissions and a 10% decrease in Scope 3 emissions from a 2019 baseline.
2
Sanofi has SBTi-validated targets aligned with a 1.5°C pathway, aiming for a 55% reduction in Scope 1 & 2 emissions and a 30% reduction in Scope 3 emissions by 2030, both from a 2019 baseline.
3
A 90% reduction in total emissions is targeted between 2019 and 2045, with a net-zero target year of 2045.
4
In 2024, 85% of operational electricity consumption was sourced from renewables.
5
The company achieved an 89% operational waste recycling/recovery rate in 2024.
6
Furthermore, 205 suppliers were engaged in a Supplier Engagement Program in 2024, covering 75% of supplier-related emissions.
7
Respect for Cultures & Communities
30
Sanofi launched over 150 collaborative projects in 2024.
1
No cultural appropriation incidents were reported in the provided evidence.
2
Safe & Smart Tech
0
No specific, recent, or comprehensive data was found in the provided articles to assess Sanofi against any of the 'Safe & Smart Tech' KPIs. While an article from April 2021 mentioned a cyberattack attempt was prevented, this single event does not provide sufficient information to score multi-year performance metrics such as data breach severity or unauthorized data use incidents, nor does it provide details on cybersecurity investment, privacy certifications, or other specific program elements.
1
Therefore, all KPIs have been omitted due to a lack of relevant evidence.
Zero Waste & Sustainable Products
-20
In 2024, Sanofi achieved an 89% operational waste diversion rate, with 76% of its sites being landfill-free.
1
The company reported a 22.5% reduction in its Waste Impact Index versus 2019.
2
Specific waste reduction initiatives include regenerating 58% of used solvents (81,185 tons in 2024)
3
and recovering over 99% of Heparin biowaste through methanization.
4
Sanofi also operates take-back programs such as Returpen for ~5.2 million injection pens annually in Denmark
5
and participates in the Cyclamed Scheme for over 600,000 kg of unwanted medicines in France.
6
The company targets at least 90% waste reuse/recycling/recovery and landfill-free operations (<1% waste to landfill) at all sites by the end of 2025.
7
Sanofi integrates eco-design principles, aiming to implement them for all new medicines and vaccines starting in 2025 and for its 20 top-selling products by 2030.
8